mProve makes mPulse, an "Electronic Patient-Reported Outcomes" platform that sends trial results to managers through stand-alone mobile-phone apps or texts, and can be adapted to message doctors and to remind patients to take their medicine. mProve says its apps are used "by 18 of the top 20" drugmakers, in more than 50 languages.
In buying a firm it said will help deliver "Bring Your Own Device" smartphone-based tools to clinical trials, Bracket is putting to work some of the capital invested by San Francisco-based Genstar Capital when it bought control of Bracket earlier this year.
"We are excited to be supporting Bracket's first acquisition" since the deal, said Genstar director David Golde in a statement. He said more acquisitions will be in the works. The firms won't say what Bracket and Genstar paid.
"These movements empower patients to become partners in their trails" and deliver more accurate trial results, Bracket chief executive Jeff Kinell said in a statement.
"Together, we are well situated for a future of tech-enabled clinical trials," added mProve CEO Jeff Lee, who founded the firm with pharmacologist Denis Curtin in 2010. Lee and Curtin said they plan to stay with the company after the acquisition.